Posts tagged ViroCell Press Release
ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”
Press ReleasesFlorence BuchananCDMO, UK CDMO, ViroCell, ViroCell Biologics, Great Ormond Street Hospital for Children, GOSH, NHS Foundation Trust, lentivirus vector, AAV vectors, cell and gene therapies, gene therapy, cell therapy, Zayed Centre for Research, 1L to 200L batch size, Scientific Advisory Board, John W. Hadden II, Matthew Shaw, CEO at Great Ormond Street Hospital, Great Ormond Street Hospital, Her Highness Sheikha Fatima bint Mubarak, Sheikh Zayed bin Sultan Al Nahyan, Founder of the United Arab Emirates, rare diseases, Great Ormond Street Hospital Children’s Charity, EQ, James Culverhouse, ViroCell Press Release
ViroCell announces new Board appointments
Press ReleasesFlorence BuchananViroCell, CDMO, UK CDMO, J. David Enloe, Martin Pule, Board of Directors, Scientific Advisory Board, gene therapy, cell therapy, viral vectors, viral vector, AAV vectors, lentivirus vectors, CGT, cell and gene therapies, Recro Pharma, Lonza, University College London, University College Hospital, Autolus Therapeutics, John W. Hadden II, Farzin Farzeneh, David Enloe, Dr. Martin Pule, ViroCell Biologics, Truell Conservation Foundation, Edmund Truell, Wellcome Trust, EQ, James Culverhouse, ViroCell Press Release, batch sizes between 1L and 200L, vector design, Daniel Truell